Vishwanath R. Lingappa, MD, PhD
Chief Technology Officer and Co-CEO and Member of the Board of Directors, Prosetta Antiviral, Inc.
Vishwanath R. Lingappa is currently Chief Technology Officer and CoCEO of Prosetta Antiviral, Inc., in San Francisco.
In these roles he
is responsible for the advancement of Prosetta's
scientific programs in both anti-viral drug development and protein bioconformatics.
He received the B.A. degree from Swarthmore College in 1975, the Ph.D. degree from The Rockefeller University in 1979, and the M.D. degree from Cornell University Medical College in 1980.
Dr. Lingappa completed residency training in Internal Medicine before joining the faculty in the Departments of Physiology and Medicine at the University of California, San Francisco (UCSF) in 1982, where he ran an NIH-funded basic research laboratory for over 20 years.
It was during this time that the core discoveries on which Prosetta's
science is based were made and refined in his
At UCSF he was heavily involved in medical student and resident teaching and training, and was author and co-editor of highly acclaimed textbooks in physiology, pathophysiology and cell biology.
has supervised some 40 pre and post-doctoral trainees, 8 of whom received the Ph.D. degree under his
has co-authored over 90 publications.
He was promoted to Professor in 1991.
Dr. Lingappa also practiced internal medicine at San Francisco General Hospital for over 26 years.
He maintains voluntary positions as Senior Scientist at the Research Institute of California Pacific Medical Center and Emeritus Professor of Physiology at UCSF.
He is recipient of a Kaiser Award for excellence in teaching (1990) and is a Fellow of the American Association for the Advancement of Science (2004).